Achievements and Limits of Current Medical Therapy of Glaucoma

Total Page:16

File Type:pdf, Size:1020Kb

Achievements and Limits of Current Medical Therapy of Glaucoma Bettin P, Khaw PT (eds): Glaucoma Surgery. 2nd, revised and extended edition. Dev Ophthalmol. Basel, Karger, 2017, vol 59, pp 1–14 ( DOI: 10.1159/000458482 ) Achievements and Limits of Current Medical Therapy of Glaucoma Pelagia Kalouda · Christina Keskini · Eleftherios Anastasopoulos · Fotis Topouzis Laboratory of Research and Clinical Applications in Ophthalmology, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki , Greece Abstract ery systems are being investigated to open new horizons Prescribing medical therapy for the treatment of glauco- in glaucoma management. Although the general rule is ma can be a complex process since many parameters to initiate glaucoma management with medical treat- should be taken into consideration regarding its achieve- ment, the limits of medical therapy should be considered ments and limits. Today, a variety of options, including to identify those patients in need of surgical manage- multiple drug classes and multiple agents within classes, ment. © 2017 S. Karger AG, Basel are available to the clinician, but caution should be given to their side effects and contraindications. Glaucoma pa- tients with preexisting ocular surface disease should be State of the Art treated with caution, and preferably with preservative- free formulations, as there is an increased risk for symp- Glaucoma is a medical term describing a group of tom deterioration. The development and use of progressive optic neuropathies characterized by fixed-combination therapies has reduced the preserva- the degeneration of retinal ganglion cells and of tive-related side effects that threaten patient adherence the retinal nerve fiber layer, resulting in changes and has minimized the washout effect of multiple instil- in the optic nerve head. Glaucoma is one of the lations. Adherence to medical treatment is not only cru- leading causes of blindness worldwide and pres- cial to its efficacy but also to its cost-effectiveness. Further ents with a significant prevalence in the popula- factors to consider are that there are patients who are tion. nonresponders to treatment, and also that the target in- It is therefore essential to accurately define and traocular pressure (IOP) cannot be reached in all patients, detect the population that should be treated for regardless of the response to treatment. The progression glaucoma and to precisely define the goal of our of damage can occur even under maximum medical intervention. In order to decide who should be treatment or maximally tolerated medical treatment, and treated for glaucoma, it has to be considered that regardless of whether low IOP levels are reached. Further- the rate of ganglion cell loss and resulting func- more, there is some conflict between medical treatment tional decay is very different among different and quality of life due to long-term everyday use and to glaucoma eyes. An older patient, diagnosed late side effects of treatment. New molecules and new deliv- in life, with a moderate rate of progression has a Downloaded by: Massachusetts Eye & Ear 205.166.145.254 - 2/20/2018 5:26:46 PM much lower risk of developing severe functional 5] . Moreover, OHTS [2] revealed the following impairment than a younger patient with the same data for the progression of OH to primary open- amount of field loss at diagnosis and rate of pro- angle glaucoma: (a) a 22% increased risk per de- gression. Moreover, a very slow rate of progres- cade of age, (b) a 10% increased risk per 1-mmHg sion may be tolerated by a patient, while a rapid increase in IOP, and (c) a 71% increased risk per rate of progression requires a considerably lower 40-μm decrease in central corneal thickness. target pressure. The goal of glaucoma treatment is to maintain Target Intraocular Pressure the patient’s visual function and related quality of Target IOP is a useful concept in glaucoma man- life, at a sustainable cost. Regarding the cost of agement. It can be described as the upper limit of treatment, factors like inconvenience, side effects, IOP that is estimated to prevent further glauco- and financial implications for the individual and matous damage or that can slow disease progres- society require careful evaluation [1] . According sion to a minimum [1] . Target IOP will vary for to the EGS guidelines, patients for whom treat- each patient depending on the IOP level before ment for glaucoma should be considered are treatment, stage of glaucoma, rate of progression those with diagnosed or suspected glaucoma who during follow-up, age and life expectancy, and the are: (a) at risk of developing functional impair- presence of other risk factors, such as exfoliation ment that will lead to a deterioration in visual syndrome. The target pressure should be reas- function-related quality of life, (b) patients with a sessed and modified regularly depending on the definitive glaucomatous visual field (VF), partic- patient’s course of the disease. ularly those with progressive disease, and (c) pa- tients with significant changes in the optic nerve Progression of Visual Field Damage head and retinal nerve fiber layer characteristic of The functional impact of glaucoma is mainly as- glaucoma. In the decision to treat glaucoma or sessed by evaluation of the VF damage. The de- not there are additional factors to consider, which tection of VF damage progression directly affects are mentioned below. the therapeutic decisions and the patients’ quality of life. Different analytical tools have been devel- Risk Assessment in Glaucoma oped in order to identify VF progression. Com- Risk factors for the progression from ocular hy- puter-assisted progression can be divided into pertension (OH) to glaucoma are: intraocular event- and trend-based analyses. pressure (IOP), age, central corneal thickness, Event-based analyses answer the question of vertical cup/disk ratio, and standard deviation whether there is disease progression or not by pattern in the VF [2, 3] . Current risk calculators comparing each follow-up examination with the that estimate an ocular hypertensive patient’s risk baseline. Using Glaucoma Change Probability of developing glaucoma over a 5-year period of (GCP) software, all VF tests are compared to time include the aforementioned parameters and baseline consisting of an average of 2 baseline should be used for populations that resemble the tests. However, this analysis is based on the total population studied in the Ocular Hypertension deviation plot, which means that it may be affect- Treatment Study (OHTS) [2] and the European ed by diffuse media opacities. On the other hand, Glaucoma Prevention Study (EGPS) [3] . Guided Progression Analysis (GPA) software is Additional risk factors that may increase the based on the pattern deviation plot, meaning it risk of glaucoma and should be considered in the evaluates progression adjusted for diffuse defects. risk assessment are exfoliation, cardiovascular Trend-based analyses are primarily designed disease, a positive family history, and myopia [4, to determine the rate of progression and show the 2 Kalouda · Keskini · Anastasopoulos · Topouzis Bettin P, Khaw PT (eds): Glaucoma Surgery. 2nd, revised and extended edition. Dev Ophthalmol. Basel, Karger, 2017, vol 59, pp 1–14 ( DOI: 10.1159/000458482 ) Downloaded by: Massachusetts Eye & Ear 205.166.145.254 - 2/20/2018 5:26:46 PM overall progression of VF defects. Trend-based considered as the most suitable initial and follow- progression displays the linear regression analysis up treatment for open-angle glaucoma, as well as of the VF index. They help the practitioner to as- for many types of chronic angle-closure glauco- sess the risk of future visual disability associated ma. There are many classes of antiglaucoma drugs with that rate of progression and the current stage that act either on the reduction of aqueous humor of damage. production or on the enhancement of the aque- ous humor outflow facility, or on both. Principles of Economic Evaluation/Cost Effectiveness First-Line Drugs Glaucoma is a chronic disease that requires life- Prostaglandin Analogues long management. Extensive and often continu- Antiglaucoma drugs were first introduced in ing therapeutic interventions are required due to glaucoma therapy in 1875, but it was in the 1990s the chronic nature of the disease. The costs (direct that prostaglandin derivatives (latanoprost ini- and indirect) and effects (short and long term) of tially and then travoprost, bimatoprost, and taflu- alternative courses of action, such as medical prost) were available for glaucoma treatment and therapies and surgery, need to be compared in or- gradually replaced β-blockers as first-line thera- der to determine cost-effective treatments for py. Their widespread adoption is due to the fact glaucoma. The direct costs are associated with di- that their IOP-lowering effect is superior to any agnosis, treatment, and monitoring, whereas the other single antiglaucoma drug, their side effects indirect costs are associated with progressive dis- appear to be very mild, and they require just once- ease and visual impairment. Moreover, short- daily administration. term effects are related to diagnosis, adverse ef- Their main mode of action is to enhance the fects, and recovery from therapies, while long- uveoscleral outflow (nonconventional pathway), term effects are related to visual outcome. reducing IOP by 25–35%. They degrade collagen It has been suggested that conventional medi- by activating a cascade which includes tissue-re- cation may be more cost-effective than one-off modeling enzymes and transcription factors. This surgery in the short term, but in the long term a leads to the opening of the intercellular spaces for successful surgery is more cost-effective because fluid drainage, which causes increased uveo- the on-going cost of medications is avoided [6] . scleral flow rates and hence decreases IOP. A re- Reported costs of glaucoma therapy vary, but ran- duction in IOP starts approximately 2–4 hours domized controlled treatment trials rarely include after topical administration. The therapeutic ef- a cost-effectiveness analysis.
Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Looking for New Classes of Bronchodilators
    REVIEW BRONCHODILATORS The future of bronchodilation: looking for new classes of bronchodilators Mario Cazzola1, Paola Rogliani 1 and Maria Gabriella Matera2 Affiliations: 1Dept of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy. 2Dept of Experimental Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy. Correspondence: Mario Cazzola, Dept of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, Rome, 00133, Italy. E-mail: [email protected] @ERSpublications There is a real interest among researchers and the pharmaceutical industry in developing novel bronchodilators. There are several new opportunities; however, they are mostly in a preclinical phase. They could better optimise bronchodilation. http://bit.ly/2lW1q39 Cite this article as: Cazzola M, Rogliani P, Matera MG. The future of bronchodilation: looking for new classes of bronchodilators. Eur Respir Rev 2019; 28: 190095 [https://doi.org/10.1183/16000617.0095-2019]. ABSTRACT Available bronchodilators can satisfy many of the needs of patients suffering from airway disorders, but they often do not relieve symptoms and their long-term use raises safety concerns. Therefore, there is interest in developing new classes that could help to overcome the limits that characterise the existing classes. At least nine potential new classes of bronchodilators have been identified: 1) selective phosphodiesterase inhibitors; 2) bitter-taste receptor agonists; 3) E-prostanoid receptor 4 agonists; 4) Rho kinase inhibitors; 5) calcilytics; 6) agonists of peroxisome proliferator-activated receptor-γ; 7) agonists of relaxin receptor 1; 8) soluble guanylyl cyclase activators; and 9) pepducins. They are under consideration, but they are mostly in a preclinical phase and, consequently, we still do not know which classes will actually be developed for clinical use and whether it will be proven that a possible clinical benefit outweighs the impact of any adverse effect.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • Antiglaucoma Compositions Containing Combinations of Alpha-2 Agonists and Beta-Blockers
    ~" ' MM II II II MM II II II Ml II II I II J European Patent Office _ _ _ © Publication number: 0 365 662 B1 Office europeen* des.. brevets , © EUROPEAN PATENT SPECIFICATION © Date of publication of patent specification: 09.03.94 © Int. CI.5: A61 K 31/47 © Application number: 89905874.7 @ Date of filing: 26.04.89 © International application number: PCT/US89/01994 © International publication number: WO 89/10126 (02.11.89 89/26) (54) ANTIGLAUCOMA COMPOSITIONS CONTAINING COMBINATIONS OF ALPHA-2 AGONISTS AND BETA-BLOCKERS. ® Priority: 26.04.88 US 186504 1075-1078 @ Date of publication of application: J. of Cardiovascular Pharmacology, vol. 2, 02.05.90 Bulletin 90/18 suppl. 1, 1980, S. 21-28 © Publication of the grant of the patent: © Proprietor: ALCON LABORATORIES INC 09.03.94 Bulletin 94/10 6201 South Freeway Ft. Worth, TX 76134(US) © Designated Contracting States: AT BE CH DE FR GB IT LI LU NL SE @ Inventor: DE SANTIS, Louis, M. 2316 Wlnton Terrace West © References cited: Fort Worth, TX 761 09(US) US-A- 4 455 317 US-A- 4 515 800 © Representative: Jump, Timothy John Simon et AM A DRUG EVALUATION, 2nd ed., 1973; al "Agent used to treat Glaucoma", pp. 675-686. Venner Shipley & Co. 20 Little Britain GLAUCOMA, vol. 1, no. 1, February 1979; London EC1A 7DH (GB) 00 S.SUGAR, pp. 9-15. CM CO Ophthalmology, vol. 96, no. 1, 1989, p. 3-7 CO m Ophthalmology, vol. 98, no. 7, 1991, p. CO 00 Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • Risk Factors Leading to Trabeculectomy Surgery Of
    Shirai et al. BMC Ophthalmology (2021) 21:153 https://doi.org/10.1186/s12886-021-01897-4 RESEARCH ARTICLE Open Access Risk factors leading to trabeculectomy surgery of glaucoma patient using Japanese nationwide administrative claims data: a retrospective non-interventional cohort study Chikako Shirai1, Satoru Tsuda1, Kunio Tarasawa2, Kiyohide Fushimi3, Kenji Fujimori2* and Toru Nakazawa1* Abstract Background: Early recognition and management of baseline risk factors may play an important role in reducing glaucoma surgery burdens. However, no studies have investigated them using real-world data in Japan or other countries. This study aimed to clarify the risk factors leading to trabeculectomy surgery, which is the most common procedure of glaucoma surgery, of glaucoma patient using the Japanese nationwide administrative claims data associated with the diagnosis procedure combination (DPC) system. Methods: It was a retrospective, non-interventional cohort study. Data were collected from patients who were admitted to DPC participating hospitals, nationwide acute care hospitals and were diagnosed with glaucoma between 2012 to 2018. The primary outcome was the risk factors associated with trabeculectomy surgery. The association between baseline characteristics and trabeculectomy surgery was identified using multivariable logistic regression analysis by comparing patients with and without trabeculectomy surgery. Meanwhile, the secondary outcomes included the rate of comorbidities, the rate of concomitant drug use and the treatment patterns of
    [Show full text]
  • REMEDY for GLAUCOMA COMPRISING Rho KINASE INHIBITOR and -BLOCKER
    Europäisches Patentamt *EP001568382A1* (19) European Patent Office Office européen des brevets (11) EP 1 568 382 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 158(3) EPC (43) Date of publication: (51) Int Cl.7: A61K 45/06, A61K 31/138, 31.08.2005 Bulletin 2005/35 A61K 31/343, A61K 31/353, A61K 31/437, A61K 31/4409, (21) Application number: 03772800.3 A61K 31/4412, A61K 31/496, (22) Date of filing: 17.11.2003 A61K 31/5377, A61K 31/551, A61P 27/06, A61P 43/00 (86) International application number: PCT/JP2003/014559 (87) International publication number: WO 2004/045644 (03.06.2004 Gazette 2004/23) (84) Designated Contracting States: • NAKAJIMA, Tadashi AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Ikoma-shi, Nara 630-0101 (JP) HU IE IT LI LU MC NL PT RO SE SI SK TR • MATSUGI, Takeshi Designated Extension States: Ikoma-shi, Nara 630-0101 (JP) AL LT LV MK • HARA, Hideaki Ikoma-shi, Nara 630-0101 (JP) (30) Priority: 18.11.2002 JP 2002333213 (74) Representative: Peaucelle, Chantal et al (71) Applicant: SANTEN PHARMACEUTICAL CO., Cabinet Armengaud Ainé LTD. 3, avenue Bugeaud Osaka 533-8651 (JP) 75116 Paris (FR) (72) Inventors: • HATANO, Masakazu Ikoma-shi, Nara 630-0101 (JP) (54) REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND &bgr;-BLOCKER (57) A subject of the present invention is to find utility of a co mbination of a Rho kinase inhibitor having a novel action and a β-blocker as a therapeutic agent for glau- coma.
    [Show full text]
  • Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews
    Supplementary Online Content Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. Published online April 27, 2016. doi:10.1001/jamacardio.2016.0218. eAppendix 1. Search Documentation Details eAppendix 2. Background, Methods, and Results of Systematic Review of Combination Drug Therapy to Evaluate for Potential Interaction of Effects eAppendix 3. PRISMA Flow Charts for Each Drug Class and Detailed Systematic Review Characteristics and Summary of Included Systematic Reviews and Meta-analyses eAppendix 4. List of Excluded Studies and Reasons for Exclusion This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix 1. Search Documentation Details. Database Organizing body Purpose Pros Cons Cochrane Cochrane Library in Database of all available -Curated by the Cochrane -Content is limited to Database of the United Kingdom systematic reviews and Collaboration reviews completed Systematic (UK) protocols published by by the Cochrane Reviews the Cochrane -Only systematic reviews Collaboration Collaboration and systematic review protocols Database of National Health Collection of structured -Curated by Centre for -Only provides Abstracts of Services (NHS) abstracts and Reviews and Dissemination structured abstracts Reviews of Centre for Reviews bibliographic
    [Show full text]
  • Phvwp Monthly Report June 2011
    30 June 2011 EMA/CHMP/PhVWP/486894/2011 Patient Health Protection Monthly report Issue number: 1106 Pharmacovigilance Working Party (PhVWP) June 2011 plenary meeting The CHMP Pharmacovigilance Working Party (PhVWP) held its June 2011 plenary meeting on 20-22 June 2011. Safety concerns Discussions on non-centrally authorised medicinal products are summarised below in accordance with the PhVWP publication policy. The positions agreed by the PhVWP for non-centrally authorised products form recommendations to Member States. For the publication policy, readers are referred to http://www.ema.europa.eu/docs/en_GB/document_library/Report/2009/10/WC500006181.pdf. The PhVWP also provides advice to the Committee for Medicinal Products for Human Use (CHMP) on centrally authorised products and products subject to ongoing CHMP procedures at the request of the CHMP. For safety updates concerning these products, readers are referred to the CHMP monthly report (http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document _listing_000190.jsp). Beta-blockers for ophthalmic use – Risk of systemic adverse reactions The PhVWP recommends harmonisation of product information across the EU for ophthalmic beta-blockers with regard to systemic adverse reactions. The PhVWP identified major differences in the summaries of product characteristics of beta-blockers authorised in the EU for ophthalmic use regarding the information on possible systemic effects between the different carteolol-containing ophthalmic products as well as in comparison
    [Show full text]
  • Short-Term Effect of Topical Antiglaucoma Medication on Tear-Film Stability, Tear Secretion, and Corneal Sensitivity in Healthy Subjects
    Clinical Ophthalmology Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH Short-term effect of topical antiglaucoma medication on tear-film stability, tear secretion, and corneal sensitivity in healthy subjects Naim Terai Background: The purpose of this study was to investigate the short-term effect of topical Matthias Müller-Holz antiglaucoma medication on tear-film stability, tear secretion, and corneal sensitivity in healthy Eberhard Spoerl subjects. Lutz E Pillunat Methods: In this prospective, double-blind crossover trial, break-up time and basal secretion (Jones test) were measured 60 minutes before, and 30, 60, and 90 minutes after topical Department of Ophthalmology, Carl Gustav Carus University Hospital, antiglaucoma drop application in 30 healthy subjects. Corneal sensitivity was measured Dresden, Germany 60 minutes before, and five, 10, and 15 minutes after drop application using a Cochet–Bonnet esthesiometer. Results: Reduction of break-up time in the latanoprost group was -23.8% after 30 minutes (P = 0.21), -26.7% after 60 minutes (P = 0.03) and -51.4% after 90 minutes (P # 0.003), which was statistically significant. Reduction of break-up time in all other treatment groups was not statistically significant. The Jones test revealed a significant reduction of basal secretion after application of brimonidine (-17.8%, P = 0.002; -22.5%, P , 0.001; -30.5%, P , 0.001), fol- lowed by apraclonidine (-10%, P = 0.06; -20.1%, P = 0.02; -22.1%, P = 0.002), latanoprost (-2.4%, P = 0.64; -18.6%, P = 0.001; -20.1%, P = 0.001) and dorzolamide (-0.5%, P = 0.9; 14.3%, P = 0.018; -17.3%, P = 0.004) at 30, 60, and 90 minutes after drop application.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]